Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT-330): a report from the Pediatric Preclinical Testing Program

BACKGROUND: Selinexor (KPT-330) is an inhibitor of the major nuclear export receptor, exportin 1 (XPO1, also termed chromosome region maintenance 1, CRM1) that has demonstrated activity in preclinical models and clinical activity against several solid and hematological cancers. PROCEDURES: Selinexor...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Pediatr Blood Cancer
Main Authors: Attiyeh, Edward F., Maris, John M., Lock, Richard, Reynolds, C. Patrick, Kang, Min H., Carol, Hernan, Gorlick, Richard, Kolb, E. Anders, Keir, Stephen T., Wu, Jianrong, Landesman, Yosef, Shacham, Sharon, Lyalin, Dmitry, Kurmasheva, Raushan T., Houghton, Peter J., Smith, Malcolm A.
Format: Artigo
Sprog:Inglês
Udgivet: 2015
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4722540/
https://ncbi.nlm.nih.gov/pubmed/26398108
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pbc.25727
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker